Blueprint Medicines Corp (NASDAQ:BPMC) does about 2.19M shares in volume on a normal day but saw 3067604 shares change hands in the recent trading day. The company now has a market cap of 8.26B USD. Its current market price is $127.85, marking a decrease of -0.04% compared to the previous close of $127.90. The 52 week high reached by this stock is $128.24 whilst the lowest price level in 52 weeks is $73.04. The script in recent trading has seen the stock touch a high of $150 and a low of $132.
10 analysts observing the Blueprint Medicines Corp (BPMC) stock have set the 12-month price targets for the company’s shares at between $132 and $150. The consensus objective for the share price is $131.53, suggesting that the stock has a potential upside of 2.8% over the period. The median price target is 9.33% away from the current levels at $141.
FactSet Research has provided data showing that 10 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 6 analysts have rated it as a buy and 4 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 02, 2025 when Wedbush downgraded the stock to “Neutral” and issued a price target of $129.
The current price level is 19.37%, 33.61%, and 35.58% away from its SMA20, SMA50, and SMA200 respectively, with the BPMC price moving above the 50-day SMA on current market day. Blueprint Medicines Corp (BPMC) stock is up 26.15% over the week and 28.11% over the past month. Its price is 46.58% year-to-date and 25.48% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.53 and -0.44 for whole year. Expected sales for next quarter are $191.05M, which analysts say will come at $720.59M for the current fiscal year and next year at $956M. In addition, estimates put the company’s current quarterly revenue at an average of $171.34M.
Its 12-month price target is $141. To reach the target analysts have set, the stock logically needs to grow 2.8 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $132, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $150.
Outstanding shares total 64.56M with insiders holding 0.86% of the shares and institutional holders owning 109.42% of the company’s common stock. The company has a return on investment of -16.74% and return on equity of -47.71%. The forward price to earnings ratio is 139.19. The beta has a value of 0.84. Price to book ratio is 24.13 and price to sales ratio is 14.69.
